ABBV
AbbVie Inc
NYSE: ABBV · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$211.32
+3.64% today
Updated 2026-04-30
Market cap
$360.63B
P/E ratio
99.95
P/S ratio
5.90x
EPS (TTM)
$2.04
Dividend yield
—
52W range
$171 – $239
Volume
7.0M
AbbVie Inc (ABBV) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
-14.4%
Last 4 quarters
Revenue YoY growth
+10.0%
Most recent quarter
EPS YoY growth
+25.5%
Most recent quarter
When is the next earnings report?
Reporting date
March 31, 2026
Consensus EPS estimate
$3.01
Fiscal period ending
2026-03-31
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+0.5%
Last 3 reports
Positive reaction rate
67%
2 of 3 quarters
Largest single-day move
+3.1%
2025-07-31
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-04 | $2.71 | -19.1% | $225.66 | $219.02 | -2.9% |
| 2025-11-05 | $1.86 | -43.1% | $215.89 | $219.04 | +1.5% |
| 2025-07-31 | $2.97 | +2.1% | $189.31 | $195.22 | +3.1% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | $3.01 | — | — | — | — |
| 2025-12-31 | $3.35 | $2.71 | -19.1% | $16.62B | +10.0% |
| 2025-09-30 | $3.27 | $1.86 | -43.1% | $15.78B | +9.1% |
| 2025-06-30 | $2.91 | $2.97 | +2.1% | $15.42B | +6.6% |
| 2025-03-31 | $2.40 | $2.46 | +2.5% | $13.34B | +8.4% |
| 2024-12-31 | $2.12 | $2.16 | +1.9% | $15.10B | +5.6% |
| 2024-09-30 | $2.92 | $3.00 | +2.7% | $14.46B | +3.8% |
| 2024-06-30 | $2.57 | $2.65 | +3.1% | $14.46B | — |
| 2024-03-31 | $2.23 | $2.31 | +3.6% | $12.31B | — |
| 2023-12-31 | $2.77 | $2.79 | +0.7% | $14.30B | — |
| 2023-09-30 | $2.86 | $2.95 | +3.1% | $13.93B | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $14.83 | $68.4B | +11.9% | 35 | high |
| 2027 (E) | $16.41 | $74.0B | +8.1% | 35 | high |
| 2028 (E) | $18.10 | $80.1B | +8.3% | 35 | medium |
| 2029 (E) | $19.95 | $87.0B | +8.5% | 35 | medium |
| 2030 (E) | $21.80 | $94.3B | +8.4% | 35 | medium |
Frequently asked questions
When does AbbVie Inc report next earnings?
AbbVie Inc (ABBV) is scheduled to report earnings on March 31, 2026. The consensus EPS estimate is $3.01.
Has AbbVie Inc beaten earnings estimates?
AbbVie Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of -14.4% over the last 4 quarters.
How does ABBV stock react to earnings?
ABBV stock has moved an average of +0.5% in the trading day following earnings over its last 3 reports, with positive reactions in 67% of those quarters.
What is AbbVie Inc's revenue growth rate?
AbbVie Inc reported year-over-year revenue growth of +10.0% in its most recent quarter, with EPS growing +25.5% year-over-year.
What is the expected EPS for ABBV in 2026?
Analysts expect AbbVie Inc to report EPS of $14.83 for fiscal year 2026, on revenue of $68.4B, based on estimates from 35 analysts.